QGEN qiagen.com: Enterprise Value-to-Sales Ratio

qiagen.com (QGEN) - corporate logo

Qiagen N.V. is developing an innovative R&D pipeline in the fields of sequencing and PCR diagnostics. The company's EV/Sales valuation allows for tracking the dynamics of this sector, where the value of 5228.25 reflects this status. The enterprise is implementing ESG standards by reducing its carbon footprint in logistics and transitioning to recyclable plastics and clean energy in the production of DNA analysis kits.

EV/Sales Multiple: Qiagen (QGEN) for 11/23/2025 - 11/20/2026

Qiagen N.V. - analytical breakdowns and key metrics (QGEN)

- market price and analyst price targets:
- cash and cash flow indicators:
Initial company analysis:Qiagen N.V., QGEN
Finished products of Qiagen Corp

To protect capital from volatility, investors must distinguish speculative growth from fundamental value. Stable demand for molecular diagnostics consumables at Qiagen N.V. (QGEN) creates a predictable cash flow, reducing overvaluation risks. By analyzing the company's current enterprise value to revenue ratio, net of debt, you determine the real price of the business per unit of sales, allowing for the timely identification of overbought asset levels.

Competitor analysis for Qiagen N.V.

TEM (tempus.com) - Company Value to Revenue Ratio|IONS: EV/Sales Multiple|Repligen Corp - Business Value to Revenue|RNA (Avidity Corp) - EV/Sales Multiple|CRISPR Therapeutics Corp - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio genedx.com (WGS)|EV/Sales Multiple ultragenyx.com (RARE)|EV/Sales Multiple BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Enterprise Value-to-Revenue Multiple|twistbioscience.com - EV/Sales Multiple|10x Genomics, Inc. - Enterprise Value-to-Revenue Coefficient|NTLA (Intellia Corp) - Company Value to Revenue|Company Value to Revenue stoketherapeutics.com|Company Value to Revenue BLFS|Company Value to Revenue Wave Life Sciences Corp (WVE)|EV/Sales Multiple MAZE|Total Company Value-to-Revenue Ratio Sionna Therapeutics Inc|Enterprise Value-to-Revenue Ratio Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Enterprise Value-to-Revenue Multiple|QURE - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple